In this article, we will discuss Ramucirumab (29). So, let’s get started.
Of the 563 Ramucirumab-treated patients in two randomized gastric cancer clinical studies, 36% were 65 and over,
while 7% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and
younger subjects, and other reported clinical experience has not identified differences in responses between the elderly
and younger patients, but greater sensitivity of some older individuals cannot be ruled out.